Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say
Source ↗
👁 0
💬 0
Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one analyst described as a “historic” launch.
Comments (0)